The convergent data derived from studies of individuals with addictions to substances in several different pharmacological classes support the idea that many of these allelic variants enhance vulnerability to many addictions. These results do not exclude additional contributions to addiction vulnerability from genomic variants that influence vulnerability to specific substances or variants that are found only in specific populations, however.
